Publications
Detailed Information
Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seo, Jun-Won | - |
dc.contributor.author | Kim, Kichun | - |
dc.contributor.author | Jun, Kang Il | - |
dc.contributor.author | Kang, Chang Kyung | - |
dc.contributor.author | Moon, Song Mi | - |
dc.contributor.author | Song, Kyoung-Ho | - |
dc.contributor.author | Bang, Ji-Hwan | - |
dc.contributor.author | Kim, Eu Suk | - |
dc.contributor.author | Kim, Hong Bin | - |
dc.contributor.author | Park, Sang Won | - |
dc.contributor.author | Kim, Nam Joong | - |
dc.contributor.author | Choe, Pyoeng Gyun | - |
dc.contributor.author | Park, Wan Beom | - |
dc.contributor.author | Oh, Myoung-don | - |
dc.date.accessioned | 2022-04-12T04:15:08Z | - |
dc.date.available | 2022-04-12T04:15:08Z | - |
dc.date.created | 2020-10-27 | - |
dc.date.created | 2020-10-27 | - |
dc.date.created | 2020-10-27 | - |
dc.date.issued | 2020-09 | - |
dc.identifier.citation | Infection and Chemotherapy, Vol.52 No.3, pp.381-388 | - |
dc.identifier.issn | 2093-2340 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177916 | - |
dc.description.abstract | Background: Tenofovir disoproxil fumarate (TDF)-induced nephrotoxicity is related to high plasma tenofovir concentrations. Tenofovir alafenamide (TAF) is a tenofovir prodrug with 90% lower plasma tenofovir concentrations. The aim of this study was to evaluate changes in tenofovir-induced nephrotoxicity in Human Immunodeficiency Virus (HIV)-positive patients who switched from TDF to TAF. Materials and Methods: We identified all HIV-positive patients who switched from elvitegravir/cobicistat/emtricitabine/TDF to elvitegravir/cobicistat/emtricitabine/TAF at a tertiary hospital. We assessed tubulopathy and renal dysfunction before TDF administration, at the time TAF was used following at least 3 months of TDF use, and 3 months after TAF administration. Tubulopathy was defined by the presence of at least three abnormalities in fractional excretion of phosphate, fractional excretion of uric acid, urinary beta 2-microglobulin, urinary N-acetyl-beta-D-glucosaminidase, glucosuria or proteinuria. Renal dysfunction was defined as decreased by more than 25% in the estimated glomerular filtration rate (eGFR) relative to baseline. Results: In 80 patients, the mean eGFR was 96.8 mL/min/1.73 m(2) before administration of TDF, 81.2 (P <0.001) at the time of change to TAF, 90.9 (P <0.001) after TAF administration. Renal dysfunction occurred in 19 patients (23.8%) after TDF use for a median 15 months, 11 (57.9%) of these patients recovered from renal dysfunction after TAF administration. Six patients (7.5%) had tubulopathy before TDF administration, 36 (45.0%) after TDF administration (P <0.001), 12 (15.0%) after TAF administration (P = 0.002). Conclusion: Tenofovir-induced nephrotoxicity in HIV-positive patients receiving TDF was mostly reversible after changing to TAF. Thus, TAF-containing regimens can be administered safely to HIV-positive patients with tenofovir-induced nephrotoxicity. | - |
dc.language | 영어 | - |
dc.publisher | Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy | - |
dc.title | Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients | - |
dc.type | Article | - |
dc.identifier.doi | 10.3947/ic.2020.52.3.381 | - |
dc.citation.journaltitle | Infection and Chemotherapy | - |
dc.identifier.wosid | 000576294800008 | - |
dc.identifier.scopusid | 2-s2.0-85095437486 | - |
dc.citation.endpage | 388 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 381 | - |
dc.citation.volume | 52 | - |
dc.identifier.kciid | ART002634235 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Eu Suk | - |
dc.contributor.affiliatedAuthor | Kim, Hong Bin | - |
dc.contributor.affiliatedAuthor | Park, Sang Won | - |
dc.contributor.affiliatedAuthor | Kim, Nam Joong | - |
dc.contributor.affiliatedAuthor | Park, Wan Beom | - |
dc.contributor.affiliatedAuthor | Oh, Myoung-don | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | HIV-INFECTED PATIENTS | - |
dc.subject.keywordPlus | KIDNEY TUBULAR DYSFUNCTION | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | EMTRICITABINE | - |
dc.subject.keywordPlus | ELVITEGRAVIR | - |
dc.subject.keywordPlus | COBICISTAT | - |
dc.subject.keywordPlus | PROPHYLAXIS | - |
dc.subject.keywordPlus | IMPAIRMENT | - |
dc.subject.keywordAuthor | Renal dysfunction | - |
dc.subject.keywordAuthor | Tubulopathy | - |
dc.subject.keywordAuthor | Tenofovir disoproxil fumarate | - |
dc.subject.keywordAuthor | Tenofovir alafenamide | - |
dc.subject.keywordAuthor | HIV | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.